In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase–mediated cancer diagnosis and therapy
- 1 December 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (12) , 3001-3013
Abstract
As part of the development of enzyme-mediated cancer imaging and therapy, a novel technology to entrap water-insoluble radioactive molecules within solid tumors, we show that a water-soluble, radioactive quinazolinone prodrug, ammonium 2-(2′-phosphoryloxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone (125IQ2-P), is hydrolyzed by alkaline phosphatase to a water-insoluble, radiolabeled drug, 2-(2′-hydroxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone (125IQ2-OH). Biodistribution data suggest the existence of two isoforms of the prodrug (IQ2-P(I) and IQ2-P), and this has been confirmed by their synthesis and characterization. Structural differences of the two isoforms have been examined using in silico molecular modeling techniques and docking methods to describe the interaction/binding between the isoforms and human placental alkaline phosphatase (PLAP), a tumor cell, membrane-associated, hydrolytic enzyme whose structure is known by X-ray crystallographic determination. Docking data show that IQ2-P, but not IQ2-P(I), fits the active binding site of PLAP favorably and interacts with the catalytic amino acid Ser92, which plays an important role in the hydrolytic process. The binding free energies (ΔGbinding) of the isoforms to PLAP predict that IQ2-P will be the better substrate for PLAP. The in vitro incubation of the isoforms with PLAP leads to the rapid hydrolysis of IQ2-P only and confirms the in silico expectations. Fluorescence microscopy shows that in vitro incubation of IQ2-P with mouse and human tumor cells causes the extracellular, alkaline phosphatase–mediated hydrolysis of the molecule and precipitation of fluorescent crystals of IQ2-OH. No hydrolysis is seen in the presence of normal mouse and human cells. Furthermore, the intratumoral injection of 125IQ2-P into alkaline phosphatase–expressing solid human tumors grown s.c. in nude rats results in efficient hydrolysis of the compound and retention of ∼70% of the injected radioactivity, whereas similar injection into normal tissues (e.g., muscle) does not produce any measurable hydrolysis (∼1%) or retention of radioactivity at the injected site. These studies support the enzyme-mediated cancer imaging and therapy technology and show the potential of such quinazolinone derivatives in the in vivo radiodetection (123I/124I) and therapy (131I) of solid tumors. [Mol Cancer Ther 2006;5(12):3001–13]Keywords
This publication has 29 references indexed in Scilit:
- Tumor-activated Prodrugs—A New Approach to Cancer TherapyCancer Investigation, 2004
- Antibody-Enzyme Conjugates for Cancer TherapyJNCI: Journal of the National Cancer Institute, 1996
- A clinical and immunohistochemical study of papillary adenocarcinoma of the prostateThe Prostate, 1995
- Antibody-Directed Enzyme Prodrug TherapyClinical Pharmacokinetics, 1994
- Prostatic Acid Phosphatase in Carcinoid TumorsAmerican Journal of Surgical Pathology, 1991
- Alkaline phosphatase isozymes in cultured human cancer cellsCellular and Molecular Life Sciences, 1985
- Immunohistochemical Markers for Prostatic CancerAnnals of the New York Academy of Sciences, 1983
- Expression of prostatic acid phosphatase in human prostate cancerCancer Letters, 1981
- Alkaline phosphatase expression in human cell lines derived from various malignanciesInternational Journal of Cancer, 1981
- TUMOR‐SPECIFIC ALKALINE PHOSPHATASE IN HEPATOMAAnnals of the New York Academy of Sciences, 1975